U.S. Residential REITs Stock News

NYSE:CPT
NYSE:CPTResidential REITs

Camden’s California Exit and Capital Shifts Might Change The Case For Investing In Camden Property Trust (CPT)

In recent weeks, Camden Property Trust completed the US$1.63 billion sale of its California portfolio, filed an US$802.87 million shelf registration for 7,250,000 common shares tied to an ESOP, updated 2026 earnings guidance, and finished a US$302.20 million share repurchase program covering 4,062,166 shares. These moves mark a significant repositioning of the portfolio toward newer Sunbelt assets while simultaneously shifting capital between buybacks and employee ownership, all against a...
NYSE:OC
NYSE:OCBuilding

What Is Behind Owens Corning (OC) Shares Climbing Today?

How Owens Corning’s Latest Earnings Shape the Story for Investors Owens Corning (OC) has attracted fresh attention after its second quarter 2026 earnings update, which paired broadly steady sales with softer profits, ongoing buybacks, and clearer guidance on upcoming segment trends and costs. See our latest analysis for Owens Corning. The earnings release and the appointment of a new CFO have come alongside brisk share price momentum for Owens Corning, with a 31.1% 90-day share price return...
NasdaqGS:GERN
NasdaqGS:GERNBiotechs

Geron (GERN) Is Up 15.6% After Raising 2026 RYTELO Revenue Guidance And Filing New ESOP Shares

In August 2026, Geron Corporation reported second-quarter 2026 results showing revenue of US$57.48 million versus US$49.04 million a year earlier, alongside a six-month net loss of US$20.32 million, and issued 2026 guidance projecting RYTELO net product revenue between US$220 million and US$240 million. The company also filed a US$6.03 million shelf registration for 4,500,000 common shares tied to an ESOP, highlighting ongoing use of equity-based compensation. We’ll now examine how Geron’s...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings. By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based...
NYSE:NBHC
NYSE:NBHCBanks

National Bank Holdings (NBHC) Affirms Dividend, Is The Valuation Discount Enough?

Dividend affirmation puts National Bank Holdings in focus National Bank Holdings (NBHC) has drawn fresh attention after its board declared a quarterly cash dividend of $0.32 per share, payable on September 15, 2026 to shareholders of record on August 28. See our latest analysis for National Bank Holdings. Alongside the confirmed dividend, National Bank Holdings shares trade at $42.62, with the 1 month share price return down 3.86% while the year to date share price return is up 12.45% and the...
NYSE:PRLB
NYSE:PRLBMachinery

Proto Labs (PRLB) Lifts Outlook As Fair Value Looks Fully Valued

Why Proto Labs Stock Is Back In Focus After Its Latest Earnings Proto Labs (PRLB) is drawing renewed investor attention after its second quarter 2026 earnings, full year outlook update, and an employee stock offering were all announced on 31 July 2026. See our latest analysis for Proto Labs. The strong second quarter update and raised 2026 revenue growth outlook have arrived alongside a sharp shift in sentiment. Proto Labs has posted a 19.5% 1 month share price return and a 92.28% 1 year...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Is Amylyx (AMLX) Quietly Rewriting Its R&D Risk‑Reward Profile As Losses Deepen Without Revenue?

Amylyx Pharmaceuticals reported Q2 2026 results in August, with a net loss of US$43.42 million compared with US$41.44 million a year earlier, and a six‑month net loss of US$84.71 million versus US$77.35 million, even as basic loss per share from continuing operations narrowed slightly year over year. The combination of a higher absolute net loss and modest per‑share loss improvement highlights the growing cost base behind Amylyx’s development pipeline at a time when it still generates no...
NYSE:TXNM
NYSE:TXNMElectric Utilities

TXNM Energy (TXNM), What Is Behind The Latest Attention?

TXNM Energy earnings event and why it matters for investors TXNM Energy (TXNM) released second quarter 2026 results on July 31, with sales and earnings figures provided for both the quarter and the first half of the year, giving investors fresh data to assess the stock. See our latest analysis for TXNM Energy. At a latest share price of $57.60, TXNM Energy has seen a 1-month share price return of 1.28%, while its 1-year total shareholder return of 3.95% contrasts with a stronger 3-year total...
NYSE:ITW
NYSE:ITWMachinery

How ITW’s Higher Dividend and New Buyback Plan Has Changed Its Investment Story

Illinois Tool Works Inc. recently announced that its Board approved a 7% increase in the regular annual cash dividend from US$6.44 to US$6.88 per share, effective with a fourth-quarter dividend of US$1.72 payable on October 9, 2026, and also authorized a new share repurchase program of up to US$6.00 billion. Alongside this capital return update, the company reported year-over-year growth in second-quarter sales and earnings and raised its 2026 earnings and revenue guidance, underscoring...
NYSE:SVV
NYSE:SVVMultiline Retail

Savers Value Village (SVV) Jumped, So What Is Behind The Fresh Attention?

Savers Value Village (SVV) has given investors fresh information to assess after reporting second quarter earnings, updating full year guidance, and highlighting early results from its ThriftIQ pricing platform rollout. See our latest analysis for Savers Value Village. The recent earnings, guidance update, ThriftIQ rollout and buyback activity appear to have caught the market's attention, with Savers Value Village recording a 1-day share price return of 12.01% and a 90-day share price return...
NasdaqGS:STOK
NasdaqGS:STOKBiotechs

Is Stoke Therapeutics' (STOK) New Shelf Filing Reframing Its Path Through Mounting Operating Losses?

In August 2026, Stoke Therapeutics reported second‑quarter 2026 results showing sales of US$9.33 million versus US$13.82 million a year earlier, alongside a net loss of US$61.62 million and basic and diluted loss per share of US$0.93 from continuing operations, compared with US$23.48 million and US$0.40 a year ago. For the first half of 2026, sales dropped to US$15.55 million from a very large prior‑year figure, while the company swung from net income of US$89.40 million to a net loss of...